CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

Cuba's Center for Genetic Engineering and Biotechnology (CIGB) highlighted today the use of national anti-COVID-19 vaccines ...

A new study published in Clinical Infectious Diseases highlights the potential of pemivibart, a long-acting monoclonal ...

In a small trial, Mass General Brigham researchers found a drug designed to treat Celiac disease supported a more rapid ...

Increased risk of long COVID seen with financial hardship, food insecurity, less than a college education, lack of social support.

Imunon has confirmed the deprioritization of its COVID-19 vaccine program. With the company’s cash reserves falling below $5 ...

Pemivibart was well tolerated and prophylactic against COVID-19 infection among adult patients with significant immunocompromising conditions.

IN late June, the Scientific Advisory Group for the Origins of Novel Pathogens (SAGO), a group of independent experts convened by the World Health Organization (WHO), published an assessment of the ...

The researchers followed participants from October 2024 to January 2025. Median age was 76 years, and 54.2% were women. By ...

Romania experienced a significant surge in COVID-19 cases in July 2025, with 1,703 new infections reported—a 232% increase ...

Surviving a severe case of COVID may put you in the same cardiovascular danger zone as someone with a long history of heart ...

The paper said that while mass die-offs have been attributed to various factors, including viruses, in many cases, there is no definitive cause.